299 results about "Inducer" patented technology

The invention discloses a fermentation method of recombinant bacillus subtilis for expressing vibrio parahaemolyticus outer membrane protein, which comprises the following steps: inoculating a recombinant bacillus subtilis strain into a liquid culture medium for activation and amplification to obtain a seed solution; transferring the seed solution into a fermentation tank according to the inoculum size of 5%-10%, controlling the temperature to be 35-37 DEG C and the pH to be 6.8-7.2, introducing sterile air and stirring, and monitoring the thallus concentration OD600 value in real time; when the OD600 value reaches 35-38, 10% of an inducer is added for pre-induction; when the OD600 value reaches 40-45, the remaining 90% of the inducer is added for main induction, and the real-time dissolved oxygen value is collected; when the real-time dissolved oxygen value is continuously higher than a first preset threshold value, the flow acceleration rate of the inducer is increased, the fermentation temperature is increased at the same time or step by step, and the increase amplitude of the dissolved oxygen value is in positive correlation with the flow acceleration rate and the temperature increase amplitude; when the OD600 value is stabilized in a preset interval, it is judged that fermentation is completed, and the recombinant bacillus subtilis thalli are obtained. The yield and quality of the vibrio parahaemolyticus outer membrane protein can be effectively improved.

The application belongs to the technical field of animal models for basic scientific research, and particularly relates to a method for establishing an acute lung injury animal model, which comprises the following steps: sending a podophyllotoxin or a podophyllotoxin reagent into a rat body through oral administration or intragastric perfusion to obtain the acute lung injury animal model. The method for establishing the acute lung injury animal model provided by the application uses the podophyllotoxin as an inducer for establishing a mouse acute lung injury model, and the mouse can orally take or intragastrically perfuse the podophyllotoxin to achieve the method, without needing a special medicine injection device, so that the method is simple in medicine taking, few in experimental steps, and does not need complex surgical operations.

The invention belongs to the technical field of synthetic biology, and particularly relates to recombinant escherichia coli for efficiently producing O-acetyl-L-homoserine as well as a construction method and application of the recombinant escherichia coli. According to the invention, CRISPR-Cas9 gene editing is combined with metabolic modification, so as to precisely integrate OAH biosynthesis key nodes: introducing and overexpressing a mutant metX gene at a genome pseudogene site to enhance the expression of homoserine acetyltransferase, knocking out byproducts such as poxB and mgsA to synthesize genes, and carrying out high-yield synthesis of OAH. Corynebacterium glutamicum thrA (anti-feedback inhibition), aspB and bacillus subtilis acsA-acuA genes (construction of an acetic acid switch) are introduced, gene expression of gltA, tpiA and the like is optimized to increase supply of precursors such as acetyl CoA and the like, and finally a stable strain without plasmids, antibiotics and inducers is obtained. The production cost is effectively reduced, and the method has the advantage of high genetic stability and shows a good application prospect in OAH industrial production.

The invention provides application of a small molecule drug for promoting triple negative breast cancer ferroptosis, and belongs to the technical field of tumor treatment. The inducer can effectively kill triple negative breast cancer cells by triggering a ferroptosis pathway. The invention discovers that the inhibitor can reduce the expression of a key protein RPTOR by inhibiting the activity of an mTORCl compound, thereby weakening the anti-oxidation defense capability of triple negative breast cancer cells, greatly enhancing the accumulation of lipid peroxide, and further strongly inducing the occurrence of ferroptosis. The component of the culture medium is a DMEM (Dulbecco Modified Eagle Medium) containing 10% of fetal calf serum, and 2 [mu] M of Torinl is added at the same time. The invention discloses a new target spot of ferroptosis of the triple-negative breast cancer, and provides a new thought for treatment of the triple-negative breast cancer.

The invention provides application of a copper death inducer in preparation of a medicine for treating osimertinib-resistant non-small cell lung cancer, and belongs to the technical field of treatment of non-small cell lung cancer. According to the invention, through high-throughput drug screening, the copper death inducer copper diethyl dithiocarbamate (CuET) and osimertinib are combined for use, so that a remarkable synergistic anti-cancer effect is achieved; furthermore, through detection of a wild type and osimertinib drug-resistant cell line model, an osimertinib sensitive and drug-resistant patient-derived organoid and a mouse xenotransplantation model, it is found that the anti-tumor effect of osimertinib can be remarkably enhanced through copper death induction, and osimertinib drug resistance is overcome. According to the technical scheme provided by the invention, osimertinib drug-resistant non-small cell lung cancer cells can be effectively killed, the curative effect of osimertinib in sensitive and drug-resistant models is remarkably enhanced, and an application scene is provided for copper death in tumor treatment.

The invention discloses a composite inducer for promoting adhesion and metamorphosis of marine bivalve mollusk larvae and an application method of the composite inducer. The composite inducer for promoting adhesion and metamorphosis of the marine bivalve mollusk larvae comprises glutamine, glutamic acid, potassium chloride, calcium chloride and taurine, and the concentration ratio of the glutamine to the glutamic acid to the potassium chloride to the calcium chloride to the taurine is 1: 1: 2 * 10: 1.7 * 10: 4. According to the application, glutamine, potassium ions, calcium ions, glutamic acid and taurine are matched, the application effect of the glutamine, the potassium ions, the calcium ions, the glutamic acid and the taurine in the aspect of improving the attachment and metamorphosis rate of the shellfish larvae is defined, the technical blank of multi-component cooperative regulation and control of the attachment and metamorphosis of the shellfish at present is filled, a new solution is provided for bivalve shellfish fry production, and the application prospect is wide. The method is of great significance in promoting healthy development of the mariculture industry.

The invention discloses a rigorous induction system for corynebacterium glutamicum and application of the rigorous induction system, and belongs to the fields of genetic engineering and microbiology. The system can be strictly regulated when an inducer is not added, and can express only after the inducer is added. More specifically, the invention relates to the reduction of leak expression of Cre recombinase by comprising a logic gate, repression regulation and RNA regulation elements, and the use thereof for mediating SCRaMbLE to produce large-scale genome random rearrangement in Corynebacterium glutamicum synthetic genomes. Particularly, the method is used for reducing the leakage expression level of Cre recombinase and keeping the moderate expression level after induction. More importantly, the rigorous induction system disclosed by the invention can be applied to genome rearrangement to obtain rearranged strains with highly diversified genotype sequences, so that the purpose of increasing the yield of target products or enhancing the stress resistance of the strains is achieved.

The invention provides an in-vitro anti-saccharification effect evaluation method and application thereof, and belongs to the technical field of skin saccharification resistance. A photoaging fibroblast model is adopted, after induction of an inducer, anti-saccharification evaluation is carried out by detecting the contents of collagen and waveform protein after application of a substance to be detected, and it is proved that the anti-saccharification effect of the anti-saccharification substance in the cell model is consistent with the result in human body effect evaluation; the evaluation method can be applied to screening and evaluation of anti-skin saccharification substances.

The invention provides application of tea catechin in preparation of a medicine for preventing and treating bortezomib-induced peripheral neuropathy. A plurality of in-vitro model results show that tea catechin can be used as a copper death inhibitor, remarkably improves related indexes of bortezomib-induced peripheral neuropathy, improves survival rates of Schwanton cells and SH-SY5Y, improves mitochondrial functions and cell cycle abnormalities of the Schwanton cells, reduces intracellular copper ion, cuprous ion and ATP levels, and can be used for preparing the copper death inhibitor for the peripheral neuropathy of the Bortezomib-induced peripheral neuropathy of the Bortezomib-induced peripheral neuropathy. Meanwhile, the death of Schwann cells and SH-SY5Y induced by the copper death inducer is reduced. In-vivo experiments show that the tea catechin plays a role in protecting functional damage of the bortezomib, and the tea catechin remarkably improves mechanical hyperalgesia, gait abnormality and pathological changes of myelin sheath and axon of mice caused by peripheral neuropathy induced by the bortezomib. The tea catechin can be used as a medicine for peripheral neuropathy induced by bortezomib, and has high clinical application value and development prospect.

The presently disclosed subject matter relates to the use of a haploid inducing line transformed such that it contains DNA encoding a cellular mechanism capable of editing a gene. This mechanism is preferentially expressed in zygotic cells. Exemplary promoters include, but are not limited to, a VSP promoter, an RZDP promoter, an SCE1 promoter, and a U3 promoter. The promoters can be obtained from arabidopsis thaliana, corn, soybean, wheat, sunflower, rice and tomato.

The invention discloses a screening and dosage determining method of a grape heat resistance inducer, and belongs to the technical field of plant stress resistance physiology and cultivation. The method comprises the following steps: soaking grape leaf wafers in inducers with different concentrations, and carrying out heat treatment under a plurality of temperature gradients; determining a chlorophyll OJIP rapid fluorescence parameter and constructing a heat resistance comprehensive index, and further calculating a normalized relative heat resistance improvement value; fitting a quantitative relation with the concentration by using a single-peak dose-effect model containing a high-dose inhibition item; statistical inference is carried out by adopting Bootstrap resampling, and a stable and effective recommended application concentration in a wide temperature range is finally determined by analyzing a common intersection or a statistical median of effective concentration intervals under multiple temperatures. The method realizes indoor rapid and quantitative screening, can realize quantitative comparison of induction intensity and dose sensitivity of different inducers under a unified evaluation system, and can be used for identifying heat resistance of grapes.

Disclosed herein is a method of using resin acids as defense gene inducers for biotic stress in a plant. Also disclosed herein are a composition including rosin and a method of using the composition as a defense gene inducer for biotic stress in a plant.

The application provides a polypeptide, a plant immune elicitor and application thereof. The polypeptide has 10 or 11 amino acid residues; the amino acid at the first position of the polypeptide is serine, and the amino acids at the 9th and 10th positions are both cysteine; if the polypeptide has 11 amino acid residues, the amino acid at the 11th position of the polypeptide is asparagine. The polypeptide can solve the problem that there is no small peptide secreted by gramineae plants in the prior art, and is suitable for the field of plant immune elicitors.

The present invention relates to a method for the expression of genes belonging to different organisms (bacteria, fungi, plants, animals and humans) in P. pastoris cells, comprising the following processing steps;i. Transfer of the gene to be expressed into the plasmid carrying the alcohol oxidase 1 (AOX1) promoterii. Cloning of the plasmid carrying the geneiii. Transfer of the recombinant plasmid carrying the AOX1 promoter and gene into the expression hostiv. Induction of the AOX1 promoter with farnesol and consequent expression of the heterologous gene.The present invention will be used in the field of recombinant protein production.

The present invention relates to a method of inducing mesenchymal-epithelial transition (MET) in a basal-like (or mesenchymal-like) cancer cell by contacting the cancer cell with an inducer of mesenchymal-epithelial transition for a time and under conditions sufficient to induce MET in the cell. Additionally, there is also provided a method of inhibiting epithelial-mesenchymal transition (EMT) of a cancer in a subject, the method comprising administering an inhibitor or regulator of lipid metabolism for a sufficient time and under conditions to inhibit epithelial mesenchymal transition (EMT) of the cancer in the subject.

The application discloses a method for creating a sorghum haploid and application thereof and belongs to the field of biotechnology and agricultural biological breeding. The application creates a sorghum haploid inducer by knocking out or knocking down a SbTET11 gene by using a CRISPR / Cas9 system. The sorghum haploid inducer is crossed with a sorghum male sterile line as a male parent to obtain a hybrid offspring, i.e. a sorghum haploid. The application identifies and confirms that a sorghum gene SbTET11 has the ability to independently induce a haploid, provides a method for creating a sorghum haploid inducer, and converts SbTET11 into an explicit and implementable technical path for practical application, which provides an effective idea for promoting the breeding of sorghum and other species.

The invention discloses application of a nerve injury induction protein 1 in preparation of a gastric cancer diagnosis and treatment product. The invention finds that the overexpression of NINJ1 not only can enhance the sensitivity of gastric cancer cells to ferroptosis by down-regulating the expression of aldehyde ketoreductase AKR1C1 / 2 / 3, but also can up-regulate the expression of MHC-I molecules on the surfaces of tumor cells, promote the presentation of tumor antigens and increase the infiltration of CD8 + T cells, so that the dual anti-tumor function is exerted; therefore, NINJ1 overexpression and an immune checkpoint inhibitor (such as a PD-L1 antibody) or a ferroptosis inducer are combined for use, so that the immunotherapy effect can be synergistically improved. The invention provides a brand new targeting strategy for overcoming the immune drug resistance of gastric cancer and improving the treatment effect, and has important clinical transformation value.

The invention belongs to the technical field of biological medicine research, and particularly relates to a cell in-vitro calcification inducer, an induction culture medium and application thereof, an aortic valve calcification in-vitro induction model and a modeling method thereof. The inducer provided by the invention is prepared from the following components in parts by weight: 2160.4 parts of beta-sodium glycerophosphate, 0.039 parts of dexamethasone, 50 parts of vitamin C and 34 parts of vitamin D. The invention further provides a culture medium formed by using the inducer and a method for modeling an aortic valve calcification in-vitro induction model by using the inducer. According to the method, osteogenic differentiation of the aortic valve interstitial cells can be stably induced within a short time, an efficient and repeatable standardized induction scheme is provided for in-vitro aortic valve calcification models and drug screening, and the method has a very good application prospect.

The invention relates to the field of microbial genetic engineering and synthetic biology, and particularly discloses a yersinia pseudotuberculosis temperature-sensitive promoter and application thereof. The screened and identified temperature-sensitive promoter element fills the blank of efficient constitutive promoter resources of yersinia pseudotuberculosis. The promoters can be used as universal gene expression regulation modules to be applied to metabolic engineering and synthetic biology research of yersinia pseudotuberculosis and other prokaryotic hosts, and are beneficial to high-efficiency expression of target protein or biosynthesis of high-value products. According to the method, the expression of the target gene can be regulated and controlled by changing the culture temperature without adding chemical inducers, so that the operation is convenient, the cost is saved, and the method has outstanding advantages in large-scale fermentation production.

The application belongs to the technical field of biological medicine, and particularly relates to application of long-chain non-coding RNA expression inhibition in esophageal cancer ferroptosis inducer sensitization. The application first reveals dynamic change of long-chain non-coding RNA ENSG00000250658 in esophageal squamous cell carcinoma metastasis based on single-cell sequencing data, detects expression of ENSG00000250658 in esophageal squamous cell carcinoma tissue and correlation with prognosis by using LNA probe-based RNA in-situ hybridization technology, and first finds that knocking down ENSG00000250658 can increase killing effect of ferroptosis inducer on esophageal squamous cell carcinoma cells. Therefore, the application provides a new technical scheme and thought for clinical diagnosis and treatment of esophageal cancer.

The application discloses application of MNT in detection of ferroptosis and chemotherapy sensitivity of lung adenocarcinoma. The application is based on a series of molecular biology experiments, and reveals that high expression of MNT inhibits ferroptosis of lung adenocarcinoma and increases chemotherapy sensitivity. Based on the results of the molecular biology experiments, the application first proposes a new use of MNT in detection of ferroptosis and chemotherapy sensitivity of lung adenocarcinoma; the expression amount of MNT of lung adenocarcinoma is detected to judge the sensitivity of lung adenocarcinoma patients to ferroptosis inducer and chemotherapy treatment, and the method has the advantages of simple operation, high sensitivity, specificity, high cost performance and application value, and provides a new way for clinically evaluating the sensitivity of lung adenocarcinoma patients to ferroptosis and cisplatin treatment.

The present invention discloses the use of Avn Anthramides C (Avn C) as an inducer of chondrocytic differentiation in Mesenchymal Stem Cells (MSCs), providing a promising approach for regenerative cartilage therapy. By employing Avn C treatment, MSCs exhibit enhanced chondrocytic differentiation and elevated expression of key specific chondrogenic extracellular matrix (ECM) factors, notably Collagen Type II (COL2A1). Furthermore, when Avn C is used in combination with Chondroitin Sulfate (CS), a synergistic effect is observed, leading to upregulation of the transcriptional activity state of SOX9, a key regulator of chondrogenesis. The disclosed invention shows significant improvements in mRNA gene expression (ACAN, LRP1, SOX9), cellular protein levels (COL2A1, SOX9, LRP1), and functional outcomes, as evidenced by the secretion of extracellular matrix proteins (FSTL-1, BGH3, CO1A1, CO1A2, and CO3A1).

The invention discloses a cascade targeting ruthenium (II) complex as well as a preparation method and application thereof. The preparation method comprises the following steps: step 1, preparing a ligand I; step 2, preparing a ligand 2; and step 3, preparing a cascade targeting ruthenium (II) complex: preparing a metal ruthenium complex through the ligand I, and carrying out coordination on the metal ruthenium complex and the ligand II to obtain the cascade targeting ruthenium (II) complex. The cascade targeting ruthenium (II) complex is novel in structure, has tumor targeting and endoplasmic reticulum targeting properties, can be used as a photosensitizer, and can generate active oxygen under illumination for photodynamic therapy of tumors. The target cascade targeting type ruthenium (II) complex is applied to preparation of anti-cancer drugs and preparation of type II ICD inducer drugs. The compound not only has excellent anti-tumor activity, but also can be used as a type II ICD inducer to induce tumor cells to generate ICD; the preparation yield is high; the repeatability is good and the like; good biocompatibility is achieved, and clinical use is facilitated.

The invention relates to the technical field of biological medicines, and particularly discloses siRNA for inhibiting CD44v6 expression in tumors and application of the siRNA. The siRNA molecule can specifically target mRNA of CD44v6, and efficient knock-down is achieved on the gene level and the protein level (the interference efficiency reaches 70%-90%); in-vitro experiments prove that the siRNA can significantly inhibit the proliferation ability and clone formation ability of gastric cancer cells (such as AGS and HGC-27); in-vivo and in-vitro experiments further show that the siRNA can enhance the sensitivity of gastric cancer cells to a ferroptosis inducer RSL3 and generate a synergistic anti-tumor effect. The invention further provides a pharmaceutical composition containing the siRNA and application of the pharmaceutical composition in preparation of drugs for treating malignant tumors such as gastric cancer, and a new strategy and means are provided for overcoming the problem that tumor progression is fast.

This invention relates to the field of biomedicine and discloses a composition for treating non-small cell lung cancer metastasis that targets replication stress vulnerability and its application. The composition includes a dual-responsive polymer prodrug, which consists of a block copolymer backbone, a matrix metalloproteinase cleavage peptide sequence coupled to the hydrophilic end, and an active molecular group coupled to the hydrophobic end based on an asymmetric grafting structure. The active molecular group comprises a replication stress inducer and an ATR kinase inhibitor. This invention maintains the amorphous phase of the micelle core through the asymmetric grafting structure, eliminating the permeation barrier caused by spontaneous crystallization of components. This amorphous core provides a proton permeation channel, ensuring the synchronous in-situ release of multiple target drugs, thereby blocking the DNA replication fork repair pathway and inducing mitotic catastrophe, maintaining the spatiotemporal overlap of multiple drug interventions in the pathological target area, and avoiding the risk of drug resistance.

The invention provides a composition for preventing and treating plant diseases and application thereof. The composition comprises antibacterial lipopeptide and a protein plant immunity inducer. Synchronous and efficient prevention and control of fungal black shank and viral PVY and CMV diseases are achieved for the first time, the prevention effect reaches 88% or above, and the industrial problem that the prevention and control spectrum of a single agent is narrow is solved.

The present disclosure provides compositions and methods for inducing protein-protein heterodimerization in the presence of salicylic acid or a synthetic derivative thereof, useful for modulating signal transduction, protein activation, and gene expression in response to chemical stimuli.

The application discloses a method for inducing T cell reprogramming into NK-like cells, comprising the following steps: (1) culturing the T cells in a culture system to obtain activated T cells; (2) adding small molecule inducers twice to the activated T cells to obtain NK-like cells; wherein the culture system in step (1) contains 1-10 v / v % serum substitute and / or platelet lysate, and does not contain fetal bovine serum. By optimizing the culture process and precisely adding drugs twice, the small molecule accumulation toxicity caused by multiple drug additions is avoided, the damage to the structure and function of the mitochondrial membrane is reduced, the mitochondrial membrane potential is significantly improved, the energy metabolism capacity of the mitochondria is enhanced, sufficient energy support is provided for the long-term survival and function maintenance of the cITNK cells, and the physiological activity of the cells is ensured from the energy metabolism level.

The present application belongs to the field of biomedicine, and relates to an inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells is based on a human mesenchymal stem cell serum-free culture medium, and is composed of the following components in a mass concentration ratio: bone morphogenetic protein-4 20-60 mg / L, bone morphogenetic protein-7 20-60 mg / L, tretinoin 2-8 mg / L, resveratrol 2-8 mg / L, icariin 2-8 mg / L, benzamide 2-8 ug / L, chloroplatinic acid hexahydrate 2-8 ug / L, ethanolamine 2-8 ug / L, erythropoietin 2-10 ug / L, and vascular endothelial growth factor 2-10 ug / L. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells has high induction efficiency.

Disclosed is the use of a composition comprising a TET pathway inhibitor and a ferroptosis inducer in the manufacture of a medicament for the treatment of malignant tumors. It is found that TET1 up-regulates expression of a ferroptosis key regulation gene GCH1 through an NF [kappa] B signal, promotes synthesis of BH4, activates a GPX4 non-dependent pathway, and plays a key hub role in controlling ferroptosis sensitivity. Through combined use of TET pathway inhibitors (including a TET inhibitor and a BH4 synthesis inhibitor), the sensitivity of tumor cells to the ferroptosis inducer can be significantly improved, and the in-vivo use dosage of the ferroptosis inducer is reduced to 1% (1 mg / kg) of the conventional treatment dosage. The composition of the TET pathway inhibitor and the ferroptosis inducer, provided by the invention, can be used for remarkably improving the ferroptosis induction curative effect of various malignant tumors, particularly ferroptosis insensitive tumors, and enhancing the safety and universality of ferroptosis induction treatment.